Muiris O’Connor

Intent: To promote the development and timely adoption of a holistic national life sciences policy joining relevant aspects of health and economic policy::To ensure policy coordination by achieving alignment of the life sciences strategy with other government policies, including in the areas of medicines access, reimbursement system reform, and promotion of clinical research, as well as alignment with government positions on EU policy files.

Details: Engagements with Irish policymakers on national life sciences policy

Intent: Timing of requirement after enactment of new legislation should be longer to give industry better opportunity to organise.

Details: Medicines Shortage - Provision in proposed EU General Pharmaceutical Legislation regarding medicines shortages prevention plan.

Intent: Highlight IPHA's position on a National Life Sciences Strategy to cross departmental representatives.

Details: Industry position on a National Life Sciences Strategy

Intent: (i) Support for IPHA EU Presidency planned events and priorities. (ii) Highlighting industry position on EU legislative files - Critical Medicines Act and BioTech Act. (iii) Raise concerns relating to the impact of UWWTD on supply of medicines and also the impact of moving OTC AMR medicines to presccription only. (iv) Support for a biopharma policy forum to coincide with European Commissions visit to Ireland in July.

Details: (i) IPHA priorities for EU Presidency and (ii) EU Presidency Events

Intent: Participate in a high level Steering Group meeting to influence the development of the first National Life Sciences Strategy.

Details: National Life Sciences Strategy

Intent: Secure alignment of the National Life Sciences Strategy with the needs of the Irish medtech sector

Details: Ireland’s National Life Sciences Strategy

Intent: Participation in consultative forums to support the development of a National Life Science Strategy in Ireland, including the contribution of perspectives on innovation, investment, competitiveness, clinical trials and supporting better patient outcomes.

Details: National Life Science Strategy engagements

Intent: To request a meeting with a senior Lilly scientist visiting from the US, on the topic of scientific research and innovation.

Details: Emerging trends in scientific research.

Intent: Update the community on legislation being developed that will affect the sector

Details: John O'Neill, PO at DOH gave a presentation at a CTI event on the upcoming Biotech Act pursuant to clinical trials. John O'Neill deputised for Muiris O'Connor

Intent: Update on the biotech act at CTI event

Details: Sent letter to Asst Sec Muiris O'Connor DOH seeking his participation in a stakeholder meeting on March 20th concerning the upcoming Biotech Act